Baird analsyt Brian Skorney has no change in his outlook to his Biogen (NASDAQ: BIIB) outlook after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE